Journal of International Oncology››2022,Vol. 49››Issue (9): 572-574.doi:10.3760/cma.j.cn371439-20220419-00112
Previous ArticlesNext Articles
Received:2022-04-19Revised:2022-05-29Online:2022-09-08Published:2022-10-21
"
| 不良反应 | 所有级别不良反应 | ≥3级不良反应 |
|---|---|---|
| 心血管系统毒性 | ||
| 高血压 | 6（8.33） | 3（4.17） |
| 窦性心动过速 | 1（1.39） | 0（0） |
| 泌尿系统毒性 | ||
| 蛋白尿 | 4（5.56） | 0（0） |
| 血尿 | 2（2.78） | 0（0） |
| 呼吸系统毒性 | ||
| 痰中带血 | 6（8.33） | 0（0） |
| 咯血 | 3（4.17） | 0（0） |
| 内分泌系统毒性 | ||
| 甲状腺功能异常 | 1（1.39） | 0（0） |
| 血脂升高 | 1（1.39） | 0（0） |
| 消化道系统毒性 | ||
| 厌食 | 12（16.67） | 0（0） |
| 腹痛 | 5（6.94） | 0（0） |
| 腹泻 | 2（2.78） | 0（0） |
| 消化道出血 | 1（1.39） | 1（1.39） |
| 吞咽困难 | 3（4.17） | 2（2.78） |
| 皮肤及附件系统毒性 | ||
| 手足综合征 | 1（1.39） | 1（1.39） |
| 口腔黏膜炎 | 1（1.39） | 1（1.39） |
| 牙周病 | 5（6.94） | 3（4.17） |
| 其他 | ||
| 乏力 | 20（27.78） | 0（0） |
| 疼痛 | 1（1.39） | 1（1.39） |
| 失眠 | 1（1.39） | 0（0） |
| [1] | Majidpoor J, Mortezaee K. Angiogenesis as a hallmark of solid tumors-clinical perspectives[J]. Cell Oncol (Dordr), 2021, 44(4): 715-737. DOI: 10.1007/s13402-021-00602-3. doi:10.1007/s13402-021-00602-3 |
| [2] | Zirlik K, Duyster J. Anti-angiogenics: current situation and future perspectives[J]. Oncol Res Treat, 2018, 41(4): 166-171. DOI: 10.1159/000488087. doi:10.1159/000488087pmid:29562226 |
| [3] | Lin B, Song X, Yang D, et al. Anlotinib inhibits angiogenesis via suppressing the activation of VEGFR2, PDGFRβ and FGFR1[J]. Gene, 2018, 654: 77-86. DOI: 10.1016/j.gene.2018.02.026. doi:S0378-1119(18)30155-0pmid:29454091 |
| [4] | Sun Y, Niu W, Du F, et al. Safety, pharmacokinetics, and antitumor properties of anlotinib, an oral multi-target tyrosine kinase inhibitor, in patients with advanced refractory solid tumors[J]. J Hematol Oncol, 2016, 9(1): 105. DOI: 10.1186/s13045-016-0332-8. doi:10.1186/s13045-016-0332-8 |
| [5] | Han B, Li K, Wang Q, et al. Effect of anlotinib as a third-line or further treatment on overall survival of patients with advanced non-small cell lung cancer: the ALTER 0303 phase 3 randomized clinical trial[J]. JAMA Oncol, 2018, 4(11): 1569-1575. DOI: 10.1001/jamaoncol.2018.3039. doi:10.1001/jamaoncol.2018.3039pmid:30098152 |
| [6] | Cheng Y, Wang Q, Li K, et al. Anlotinib vs placebo as third- or further-line treatment for patients with small cell lung cancer: a randomised, double-blind, placebo-controlled Phase 2 study[J]. Br J Cancer, 2021, 125(3): 366-371. DOI: 10.1038/s41416-021-01356-3. doi:10.1038/s41416-021-01356-3 |
| [7] | Li D, Chi Y, Chen X, et al. Anlotinib in locally advanced or metastatic medullary thyroid carcinoma: a randomized, double-blind phase ⅡB trial[J]. Clin Cancer Res, 2021, 27(13): 3567-3575. DOI: 10.1158/1078-0432.CCR-20-2950. doi:10.1158/1078-0432.CCR-20-2950 |
| [8] | Chi Y, Fang Z, Hong X, et al. Safety and efficacy of anlotinib, a multikinase angiogenesis inhibitor, in patients with refractory metastatic soft-tissue sarcoma[J]. Clin Cancer Res, 2018, 24(21): 5233-5238. DOI: 10.1158/1078-0432.CCR-17-3766. doi:10.1158/1078-0432.CCR-17-3766pmid:29895706 |
| [9] | Sun Y, Zhou A, Zhang W, et al. Anlotinib in the treatment of advanced hepatocellular carcinoma: an open-label phase Ⅱ study (ALTER-0802 study)[J]. Hepatol Int, 2021, 15(3): 621-629. DOI: 10.1007/s12072-021-10171-0. doi:10.1007/s12072-021-10171-0 |
| [10] | Chi Y, Shu Y, Ba Y, et al. Anlotinib monotherapy for refractory metastatic colorectal cancer: a double-blinded, placebo-controlled, randomized phase Ⅲ trial (ALTER0703)[J]. Oncologist, 2021, 26(10): e1693-e1703. DOI: 10.1002/onco.13857. doi:10.1002/onco.13857 |
| [11] | Zhou AP, Bai Y, Song Y, et al. Anlotinib versus sunitinib as first-line treatment for metastatic renal cell carcinoma: a randomized phase Ⅱ clinical trial[J]. Oncologist, 2019, 24(8): e702-e708. DOI: 10.1634/theoncologist.2018-0839. doi:10.1634/theoncologist.2018-0839 |
| [12] | Huang J, Xiao J, Fang W, et al. Anlotinib for previously treated advanced or metastatic esophageal squamous cell carcinoma: a double-blind randomized phase 2 trial[J]. Cancer Med, 2021, 10(5): 1681-1689. DOI: 10.1002/cam4.3771. doi:10.1002/cam4.3771 |
| [13] | Si X, Zhang L, Wang H, et al. Management of anlotinib-related adverse events in patients with advanced non-small cell lung cancer: experiences in ALTER-0303[J]. Thoracic Cancer, 2019, 10(3): 551-556. DOI: 10.1111/1759-7714.12977. doi:10.1111/1759-7714.12977pmid:30666799 |
| [14] | Elad S, Yarom N, Zadik Y, et al. The broadening scope of oral mucositis and oral ulcerative mucosal toxicities of anticancer therapies[J]. CA Cancer J Clin, 2022, 72(1): 57-77. DOI: 10.3322/caac.21704. doi:10.3322/caac.21704 |
| No related articles found! |
| Viewed | ||||||
| Full text |
|
|||||
| Abstract |
|
|||||
